文献速递神经眼科

视神经炎治疗试验患者中髓鞘少突胶质细胞糖蛋白抗体和水通道蛋白4-IgG的阳性率

Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

该研究对视神经炎治疗试验(ONTT)中177例急性视神经炎患者的血清进行水通道蛋白4(AQP4)-IgG和髓鞘少突胶质细胞糖蛋白(MOG)-IgG检测,发现3例(1.7%)MOG-IgG阳性,无AQP4-IgG阳性。MOG-IgG阳性患者均伴视盘水肿,全部视力完全恢复,15年随访无多发性硬化发生。作者认为MOG-IgG相关疾病与多发性硬化不同,孤立性视神经炎中这些抗体可能较既往报道少见。

要点

  • ONTT队列177例急性视神经炎患者中,MOG-IgG阳性3例(1.7%),AQP4-IgG均阴性。
  • 3例MOG-IgG阳性患者均伴视盘水肿,视力完全恢复,15年随访无多发性硬化。
  • 作者认为MOG-IgG相关疾病与多发性硬化不同,孤立性视神经炎中AQP4-IgG和MOG-IgG可能较既往报道少见。

核心结论

  • ONTT中MOG-IgG阳性率低,未发现AQP4-IgG阳性患者。
  • MOG-IgG阳性患者特征支持既往描述的MOG-IgG视神经炎表型。
  • MOG-IgG相关疾病似乎是与多发性硬化不同的疾病实体。
  • 总体而言,孤立性视神经炎中AQP4-IgG和MOG-IgG可能较既往报道少见。

研究设计与样本

  • 研究为随机临床试验ONTT的随访研究,ONTT于1988年7月1日至1991年6月30日开展。
  • 血清AQP4-IgG和MOG-IgG检测于2017年1月1日至4月30日进行,采用流式细胞术活细胞转染细胞法。
  • 共纳入来自13个学术转诊中心的177例ONTT急性视神经炎患者,均有可分析血清。

主要发现

  • 177例患者中女性135例、男性42例,平均年龄32.8岁(SD 6.9)。
  • 3例(1.7%)MOG-IgG阳性,无一例AQP4-IgG阳性。
  • 3例MOG-IgG阳性患者就诊时均有视盘水肿,其中2例 later 出现一次复发性视神经炎。
  • 3例MOG-IgG阳性患者视力均完全恢复,均无皮质类固醇依赖,但1例残留周边视野缺损。
  • 3例MOG-IgG阳性患者磁共振成像均无脱髓鞘病灶,15年随访时均未发生多发性硬化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autoantibodies to aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) are recently established biomarkers of autoimmune optic neuritis whose frequency and accompanying phenotype, especially for MOG-IgG, are still being characterized. The Optic Neuritis Treatment Trial (ONTT) was a well-known randomized clinical trial in optic neuritis; therefore, knowledge of the serostatus and accompanying phenotype of these patients would be useful to determine the frequency of these antibodies in patients presenting with typical monocular optic neuritis and their outcomes. OBJECTIVES: To determine the AQP4-IgG and MOG-IgG serostatus of patients within the ONTT and describe the clinical features of seropositive patients. DESIGN, SETTING, AND PARTICIPANTS: In this follow-up study of the randomized clinical trial, ONTT, conducted between July 1, 1988, and June 30, 1991, analysis of serum for AQP4-IgG and MOG-IgG was performed from January 1 to April 30, 2017. A total of 177 patients from the ONTT with acute optic neuritis and serum available for analysis were enrolled from 13 academic referral centers. INTERVENTIONS: Analysis of serum for AQP4-IgG and MOG-IgG was performed at Mayo Clinic Neuroimmunology Laboratory in 2017 with a flow cytometry, live cell, AQP4- and MOG-transfected cell-based assay. MAIN OUTCOMES AND MEASURES: Aquaporin-4-IgG and MOG-IgG serostatus. RESULTS: Of the 177 patients in the study (135 women and 42 men; mean [SD] age, 32.8 [6.9] years), 3 were positive for MOG-IgG (1.7%) and none were positive for AQP4-IgG. All 3 patients positive for MOG-IgG had disc edema at presentation. Two patients later had a single episode of recurrent optic neuritis. All 3 patients had complete recovery of visual acuity, and none were corticosteroid dependent, although peripheral visual field loss persisted in 1 patient. None of the 3 patients positive for MOG-IgG had demyelinating lesions on magnetic resonance imaging scans, and none had developed multiple sclerosis at the 15-year follow-up. CONCLUSIONS AND RELEVANCE: Frequency of MOG-IgG was rare in the ONTT, and AQP4-IgG was not found in patients in the ONTT. Characteristics of patients positive for MOG-IgG in the ONTT support the previously described phenotype of MOG-IgG optic neuritis. Myelin oligodendrocyte glycoprotein-related disease appears to be a different entity than multiple sclerosis. Overall, AQP4-IgG and MOG-IgG may be less common in isolated optic neuritis than previously reported.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chen JJ, Tobin WO, Majed M, et al. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. 2018. PMID: 29470571. doi:10.1001/jamaophthalmol.2017.6757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。